首页> 美国卫生研究院文献>PLoS Clinical Trials >Identification of a Highly Antigenic Linear B Cell Epitope within Plasmodium vivax Apical Membrane Antigen 1 (AMA-1)
【2h】

Identification of a Highly Antigenic Linear B Cell Epitope within Plasmodium vivax Apical Membrane Antigen 1 (AMA-1)

机译:间日疟原虫顶膜抗原1(AMA-1)中的高度抗原线性B细胞表位的鉴定。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Apical membrane antigen 1 (AMA-1) is considered to be a major candidate antigen for a malaria vaccine. Previous immunoepidemiological studies of naturally acquired immunity to Plasmodium vivax AMA-1 (PvAMA-1) have shown a higher prevalence of specific antibodies to domain II (DII) of AMA-1. In the present study, we confirmed that specific antibody responses from naturally infected individuals were highly reactive to both full-length AMA-1 and DII. Also, we demonstrated a strong association between AMA-1 and DII IgG and IgG subclass responses. We analyzed the primary sequence of PvAMA-1 for B cell linear epitopes co-occurring with intrinsically unstructured/disordered regions (IURs). The B cell epitope comprising the amino acid sequence 290–307 of PvAMA-1 (SASDQPTQYEEEMTDYQK), with the highest prediction scores, was identified in domain II and further selected for chemical synthesis and immunological testing. The antigenicity of the synthetic peptide was identified by serological analysis using sera from P. vivax-infected individuals who were knowingly reactive to the PvAMA-1 ectodomain only, domain II only, or reactive to both antigens. Although the synthetic peptide was recognized by all serum samples specific to domain II, serum with reactivity only to the full-length protein presented 58.3% positivity. Moreover, IgG reactivity against PvAMA-1 and domain II after depletion of specific synthetic peptide antibodies was reduced by 18% and 33% (P = 0.0001 for both), respectively. These results suggest that the linear epitope SASDQPTQYEEEMTDYQK is highly antigenic during natural human infections and is an important antigenic region of the domain II of PvAMA-1, suggesting its possible future use in pre-clinical studies.
机译:心尖膜抗原1(AMA-1)被认为是疟疾疫苗的主要候选抗原。先前对间日疟原虫AMA-1(PvAMA-1)的自然获得性免疫的免疫流行病学研究表明,针对AMA-1域II(DII)的特异性抗体的患病率更高。在本研究中,我们证实了来自自然感染个体的特异性抗体反应对全长AMA-1和DII都具有高度反应性。此外,我们证明了AMA-1与DII IgG和IgG亚类反应之间的密切联系。我们分析了Bv线性表位与固有的非结构化/无序区(IUR)共同发生的PvAMA-1的主要序列。已在结构域II中鉴定出具有最高预测得分的B细胞表位,该表位包含PvAMA-1(SASDQPTQYEEEMTDYQK)氨基酸序列290-307,并进一步选择用于化学合成和免疫学测试。通过血清学分析,使用间日疟原虫感染个体的血清进行血清学分析,鉴定了该合成肽的抗原性,该个体已知仅对PvAMA-1胞外域,仅对域II或对两种抗原均具有反应性。尽管合成肽被域II特异的所有血清样品所识别,但仅对全长蛋白质具有反应性的血清呈阳性,占58.3%。此外,在耗尽特定合成肽抗体后,针对PvAMA-1和域II的IgG反应性分别降低了18%和33%(两者均为P = 0.0001)。这些结果表明,线性表位SASDQPTQYEEEMTDYQK在人类自然感染过程中具有高度抗原性,并且是PvAMA-1结构域II的重要抗原区域,表明其可能在临床前研究中使用。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号